NEW YORK, Nov. 2 /PRNewswire-FirstCall/ -- Lev Pharmaceuticals, Inc. today announced that Joshua Schein, Ph.D., Chief Executive Officer of Lev Pharmaceuticals, Inc. is scheduled to present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference at the New York Palace Hotel in New York City on Wednesday, November 9th at 3:50 p.m. EST. Dr. Schein will provide an update on the Company’s clinical program for its lead product candidate, C1-esterase inhibitor (C1-INH) for hereditary angioedema (HAE), which is currently being studied in a Phase III clinical trial for both the treatment and prevention of inflammatory attacks.
About Lev Pharmaceuticals, Inc.
Lev Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Lev Pharmaceuticals’ product candidates are based on C1-esterase inhibitor (“C1-INH”), a human plasma protein that mediates inflammation and is potentially applicable as a treatment for a range of medical indications. In addition to the treatment of hereditary angioedema, Lev Pharmaceuticals is also developing C1-INH for the treatment of acute myocardial infarction, or heart attack, and selective other diseases and disorders in which inflammation is known or believed to play an underlying role.
Contacts: Joshua D. Schein, Ph.D. Chief Executive Officer Lev Pharmaceuticals, Inc. 212-682-3096 jschein@levpharma.com Sharon Weinstein Director of Investor Relations Noonan Russo 212-845-4271 sharon.weinstein@eurorscg.com
Lev Pharmaceuticals, Inc.
CONTACT: Joshua D. Schein, Ph.D., Chief Executive Officer of LevPharmaceuticals, Inc., +1-212-682-3096, jschein@levpharma.com; or SharonWeinstein, Director of Investor Relations of Noonan Russo, +1-212-845-4271,sharon.weinstein@eurorscg.com, for Lev Pharmaceuticals, Inc.
